You are here: Industry Insights > Roche

News List

How Roche Fine-tuned An Old Drug to Keep Making Profits bloomberg.com
August 24, 2017
The pharma company reformulated a cancer drug to treat MS and jacked up the price.
MIMETAS collaborates with Roche to develop new chip technology biospectrumasia
August 21, 2017
MIMETAS works with Roche on new chip technology system which is designed to support intestinal permeability assessment.
A Review of the Biggest Big Pharmas, New and Old fiercepharma
August 11, 2017
From perennial giants Johnson & Johnson, Pfizer and Novartis to the buyout targets to the newest names at the top of revenue rankings of pharmaceautical industry, the numbers tell only part of the truths.
Roche out-licneses lebrikizumab to Dermira pharmatimes
August 10, 2017
Roche has agreed to out-license certain rights to its invesitgational atropic dermatitis drug lebrikizumab to Demira in a deal that could be worth more than $1.4 billion.
Roche’s Tecentriq hits trouble with NICE in bladder cancer pharmaphorum
August 04, 2017
NICE has said Roche’s cancer immunotherapy Tecentriq (atezolizumab) should not receive regular NHS funding as a treatment for bladder cancer in first draft guidance...
UK NICE invites Roche to submit Cancer Drugs Fund proposal for atezolizumab pharmaceutical-technology
August 04, 2017
The UK National Institute for Health and Care Excellence (NICE) has invited Swiss healthcare company, Roche, to submit a Cancer Drugs Fund (CDF) proposal for its urothelial cancer drug, atezolizumab.
NICE turns down Tecentriq in bladder cancer but suggests Roche try again for some patients fiercepharma
August 03, 2017
Roche and England’s drug cost watchdog NICE are again in an arm-wrestling match, this time over the use of Roche’s cancer drug Tecentriq for metastatic urothelial cancer.
Roche’s Herceptin facing further biosimilar threats in US pharmaphorum
August 03, 2017
Roche’s breast cancer blockbuster Herceptin could face further competition in the US when its patent expires in the coming years...
Amgen, Allergan’s Herceptin biosimilar filed in the US pharmatimes
August 02, 2017
US biotech giant Amgen and Dublin, Ireland-based Allergan have now filed ABP 980 - a biosimilar version of Roche’s blockbuster biologic trastuzumab - with the US Food and Drug Administration.
Roche reports strong performance in the first half of 2017 worldpharmanews
August 02, 2017
Group sales rose 5% to CHF 26.3 billion. Core EPS grew 6%, ahead of sales.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 45 46 Next page